MIT Validates Serva Energy’s Novel Production Method of Life-saving Actinium-225 Isotope

Serva Energy’s sample measurement of the rare, cancer-killing medical isotope Actinium-225 has been validated by the Massachusetts Institute of Technology (MIT) Nuclear Research Laboratory.

It’s the latest milestone in Serva’s development of commercial quantities of Actinium-225 (Ac-225) needed for next-generation Targeted Alpha Therapies.Continue reading

City of Hope, TGen awarded five-year, $4.5 million grant to advance liquid biopsy for pancreatic cancer

  • City of Hope-led consortium seeks to validate noninvasive screening test for pancreatic ductal adenocarcinoma through large-scale cohort
  • Inclusion of diverse populations is crucial for advancing understanding of these diseases, promoting health equity, and ensuring that medical research and treatments are inclusive and effective for all populations

Continue reading

HonorHealth Research Institute, City of Hope and TGen lead international team in creating ‘robust’ early-detection method for pancreatic cancer

SCOTTSDALE, Ariz. — Oct. 18, 2023 — In a significant breakthrough that could eventually extend the survival of patients with one of the deadliest of all malignancies, an international team of researchers have devised an investigational blood test that might one day help doctors detect pancreatic cancer earlier.Continue reading

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

ROOT, Switzerland–Oct 12, 2023 (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.Continue reading